网站地图

Overview

Team

Leadership Team

Board of Directors

Milestones

Radio Therapeutics

Pipeline

Programs

UniRDC^TM

Radio Technology

Manufacturing

Logistics

Press Releases

Full-Life Technologies Launches with $10M Seed Round Financing to Advance Its Nuclear Technology & Nuclear Medicines Businesses

Full-Life Technologies Announces Senior Executive Team Appointments

Full-Life Technologies Completes $37 Million (USD)Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform

Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board

Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline

Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer

Full-Life Technologies Announces Land Purchase in Belgium to Establish GMP Manufacturing Facility for Radiopharmaceutical Drug Production

Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals

Global radiotherapeutics company Full-Life Technologies announces USD $47.3 million Series B financing, Prosperity7 Ventures jointly leads the round

Full-Life Technologies and Eckert & Ziegler Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

Full-Life Technologies will present preclinical data of its novel PSMA-targeted RDC program ²²⁵Ac-FL-020 at the AACR Annual Meeting 2024

Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction

Full-Life Technologies Announced the Poster Presentations of preclinical data of its novel PSMA-targeted RDC program ²²⁵Ac-FL-020 at the AACR Annual Meeting 2024

Full-Life Technologies will showcase preclinical data of its NTSR1-targeted RDC program FL-091 in an oral presentation at the 2024 SNMMI Annual Meeting

Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer

Full-Life Technologies Announces Clearance from FDA of IND Application for ²²⁵Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting

Full-Life Technologies Granted FDA Fast Track Designation for ²²⁵Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors

Full-Life Technologies Attends the Morgan Stanley 22nd Annual Global Healthcare Conference

Full-Life Technologies to Present Three Top Rated Oral Presentations at the 37th Annual Congress of the European Association of Nuclear Medicine

Full-Life Technologies Announced the Progress of its Radioisotope Manufacturing Facility in Belgium

Full-Life Technologies to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Full-Life Technologies to Present Research on FL-031 and FL-801 at AACR 2025

Full-Life Technologies Announces Appointment of Debora Barton, MD, as Chief Medical Officer

Full-Life Technologies to Participate in the ASCO 2025

Media Reports

FIERCE Biotech | Full-Life wants more, acquires New Jersey biotech in efforts to dominate radiopharmaceutical R&D

ENDPOINTS NEWS | With ops spanning Belgium and China, Full-Life inks $245M buyout to beef up radiopharma pipeline

ENDPOINTS NEWS | Trailing Novartis and Eli Lilly, radiopharmaceuticals startup Full-Life Technologies nabs $63M to test new PSMA drug

Presentation

²²⁵Ac-FL-020 is a novel PSMA-targeting radionuclide drug conjugate (RDC) with superior in vivo anti-tumor activity

Development of ¹⁷⁷Lu-FL-091 for the treatment of NTSR1-positive cancers